LabBook September 5, 2014

University of Chicago Medicine nurses practice their diagnostic skills in the Simulation Center on Sept. 2, 2014. (Photo by Ashley Heher)

University of Chicago Medicine nurses practice their diagnostic skills in the Simulation Center on Sept. 2, 2014. (Photo by Ashley Heher)

This week’s rundown of recent research publications of note from University of Chicago scientists and physicians:

Human Immunodeficiency Virus and Coinfection with Hepatitis B and C: Lindsay Petty, Jennifer Steinbeck, Kenneth Pursell, Donald Jensen — Infectious Disease Clinics of North America

From the intro: “A disproportionate number of people with human immunodeficiency virus (HIV) are affected by viral hepatitis compared with the general population, because they are at higher risk due to similar routes of transmission of these blood-borne pathogens, as well as chronic persistence of virus in most hosts.1 Of all patients with HIV infection in the United States, about 10% are coinfected with hepatitis B virus (HBV) and 25% are coinfected with hepatitis C virus (HCV). Therefore, in total about one-third of the HIV population is affected by viral hepatitis.2 and 3 In the era of highly active antiretroviral therapy (HAART), liver disease has become a leading cause of morbidity and mortality in HIV-infected persons and is the second leading cause of death in HIV-infected individuals, causing 9% of deaths.4 Coinfection with viral hepatitis, caused by either HBV or HCV, is the main cause of liver disease. Multiple issues arise, including the dual toxicities to the liver from both viral hepatitis and ART, as well as the potential need for altering the selection of antiretroviral therapy (ART) in the setting of potential treatment of viral hepatitis, possibly affecting both the timing and the choice of therapy. In the setting of the release of new direct-acting antiviral (DAA) agents, the treatment of HIV/HCV-coinfected patients is rapidly evolving and improving.”

Curricular Content of Internal Medicine Residency Programs: A Nationwide Report: including Vineet Arora — The American Journal of Medicine

From the abstract: “Inadequate physician skills after the completion of residency training is a growing public concern. Calls for reform have been reiterated by multiple stakeholders. In response, the Accreditation Council for Graduate Medical Education (ACGME) has mandated that programs adopt new curricula so that residents acquire the skills physicians need to practice in today’s complex health care system … The aim of this study is to describe the curricular content of today’s internal medicine residency programs and compare our findings to the RAND report [a descriptive study of GME curricular content via semi-structured interviews with a representative sample of internal medicine residencies].”

Targeted Analysis of Whole Genome Sequence Data to Diagnose Genetic Cardiomyopathy: Jessica Golbus, Megan Puckelwartz, Lisa Dellefave-Castillo, John Fahrenbach, Viswateja Nelakuditi, Lorenzo Pesce, Peter Pytel and Elizabeth McNally — Circulation: Cardiovascular Genetics

From the abstract: “Cardiomyopathy is highly heritable but genetically diverse. At present, genetic testing for cardiomyopathy uses targeted sequencing to simultaneously assess the coding regions of more than 50 genes. New genes are routinely added to panels to improve the diagnostic yield. With the anticipated $1000 genome, it is expected that genetic testing will shift towards comprehensive genome sequencing accompanied by targeted gene analysis. Therefore, we assessed the reliability of whole genome sequencing and targeted analysis to identify cardiomyopathy variants in 11 subjects with cardiomyopathy.”

Incidence and Predictors of Clinical Response, Re-induction Dose, and Maintenance Dose Escalation with Certolizumab Pegol in Crohn’s Disease: including Adam Stein, David Rubin, and Russell Cohen — Inflammatory Bowel Diseases

From the abstract: “Certolizumab pegol (CERT) is indicated for reducing the signs and symptoms of Crohn’s disease (CD) and maintaining clinical response. Patients losing response received an extra “capture” re-induction dose in the PRECiSE 4 study. We examined the use of certolizumab in a retrospective cohort of patients with CD at a single inflammatory bowel disease center … The majority of patients receiving re-induction dosing did not achieve a sustained clinical response. Previous treatment with anti-tumor necrosis factor therapy was associated with reduced responses, suggesting that CERT may be more effective as an initial anti-tumor necrosis factor therapy.”

About Matt Wood (531 Articles)
Matt Wood is a senior science writer and manager of communications at the University of Chicago Medicine & Biological Sciences Division.
%d bloggers like this: